RSLV-132 is not a first-line treatment, but it may be particularly promising for some of the 60 to 80 percent of lupus patients with skin manifestations.
A new tool using a tablet and validated outcome measures has been initiated at Cleveland Clinic. It enables rheumatologists to obtain the information they need to make informed treatment decisions in real time and before they enter the patient’s room.
A training infrastructure for our rheumatology fellows provides a full circle experience of evidence-based, didactic learning and its application to the direct care of patients with vasculitis.
A brief update on Zika for practicing rheumatologists in North America.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The treatment of vasculitis has evolved significantly over the past 20 years, in some instances providing physicians and patients with a diverse range of options. With these options come questions of when to use these different therapies and how to weigh their risks and benefits.
As advances in genomic medicine improve the diagnosis of autoinflammatory disease and help us recognize new disorders in this class, the need for coordinated care intensifies.
Enhanced protocols for CVD risk assessment as well as more comprehensive research regarding CVD in PsA are urgently needed.
These nine slides depict calcinosis, including the case of a 29-year-old female whose dystrophic calcinosis progressed relentlessly, ultimately covering her entire body like an exoskeleton.
Biologic Therapies VII Summit in April 2-17 will help clinicians understand and harness the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.